| 24736079 |
Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib
Azada, M,
Ignatius Ou, SH,
Klempner, SJ,
Herman, JM,
Ali, SM,
He, J,
Casey, C,
Siwak-Tapp, C,
Miller, VA,
Hsiang, DJ,
Kain, TS
|
J Thorac Oncol |
2014 |
| 29964125 |
Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases
Heinrich, MC,
Kent, JD,
Klug, LR
|
Pharmacol. Ther. |
2018 |
| 21345110 |
Crizotinib in anaplastic large-cell lymphoma
Messa, C,
Pogliani, EM,
Gambacorti-Passerini, C
|
N. Engl. J. Med. |
2011 |
| 23201355 |
Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition
Roskoski, R
|
Pharmacol. Res. |
2013 |
| 17185414 |
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Melnick, JS,
Ding, P,
Liu, Y,
Li, N,
Hood, TL,
Wan, Y,
Li, L,
Schultz, PG,
Warmuth, M,
Kim, S,
Steensma, R,
Galkin, AV,
Chopiuk, G,
Gray, NS,
Sun, F,
Jiang, J,
Xia, G
|
Proc. Natl. Acad. Sci. U.S.A. |
2007 |
| 23239810 |
Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors
Ceccon, M,
Mologni, L,
Scapozza, L,
Bisson, W,
Gambacorti-Passerini, C
|
Mol. Cancer Res. |
2013 |
| 32573700 |
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma
Chiarle, R,
Schleiermacher, G,
Lambilliotte, A,
Forde, SD,
Lobello, C,
Pacquement, H,
Attarbaschi, A,
Probst, NA,
Prokoph, N,
Malik, V,
Barbieri, I,
Gambacorti-Passerini, C,
Sharma, GG,
Klapper, W,
Liang, HC,
Mologni, L,
Woessmann, W,
Pospisilova, S,
Wang, Q,
Pervez, S,
Ducray, SP,
Geoerger, B,
Landman-Parker, J,
Turner, SD,
Montes-Mojarro, IA,
Monahan, JM,
Matthews, JD,
Kenner, L,
Luan, SL,
Merkel, O,
Vassal, G,
Jauch, R,
Burke, GAA,
Larose, H,
Bahnsen, K,
Janíková, A,
Brugières, L,
Lee, LC,
Karaca-Atabay, E
|
Blood |
2020 |
| 26464158 |
ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression
Klempner, SJ,
Ali, SM,
Ou, SH,
Milliken, JC,
Miller, VA,
Azada, MC
|
Lung Cancer |
2016 |
| 31780656 |
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status
de Los Fayos Alonso, IG,
Probst, NA,
Prokoph, N,
Tangermann, S,
Martinez, S,
Pastor, J,
Turner, SD,
Manners, E,
Luo, J,
Matthews, JD,
Kenner, L,
Kodajova, P,
Merkel, O,
Reynolds, CP,
Amos Burke, GA,
Han, M,
Blanco-Aparicio, C,
Jahangiri, L,
Högler, S,
Lim, HK,
Lee, LC,
Trigg, RM
|
Nat Commun |
2019 |
| 29455642 |
Role and targeting of anaplastic lymphoma kinase in cancer
Troiani, T,
Viscardi, G,
Morgillo, F,
Fasano, M,
Martinelli, E,
Ciardiello, F,
Della Corte, CM,
Di Liello, R
|
Mol. Cancer |
2018 |
| 25421750 |
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma
Piazza, R,
Ceccon, M,
Giudici, G,
Mologni, L,
Fontana, D,
Gambacorti-Passerini, C,
Pirola, A
|
Mol. Cancer Res. |
2015 |
| 27780853 |
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Mohemmad, Q,
Keats, J,
Dalgarno, D,
Jang, HG,
Anjum, R,
Wang, Y,
Zou, D,
Nadworny, S,
Huang, WS,
Miller, D,
Moran, L,
Eichinger, L,
Miret, J,
Zhang, S,
Shakespeare, WC,
Ning, Y,
Liu, S,
Squillace, R,
Ye, E,
Rivera, VM,
Clackson, T,
Wardwell, SD,
Wang, F,
Narasimhan, N,
Zhou, T,
Song, Y,
Zhu, X
|
Clin. Cancer Res. |
2016 |
| 21154129 |
Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases
Shapiro, GI,
Rodig, SJ
|
Curr Opin Investig Drugs |
2010 |
| 28122866 |
Targeting ALK: Precision Medicine Takes on Drug Resistance
Shaw, AT,
Riely, GJ,
Lin, JJ
|
Cancer Discov |
2017 |
| 24670165 |
Ceritinib in ALK-rearranged non-small-cell lung cancer
Thomas, M,
Solomon, BJ,
Boral, AL,
Shaw, AT,
Liu, G,
Kim, DW,
Tan, DS,
Chow, LQ,
Sharma, S,
Engelman, JA,
Schuler, M,
Mehra, R,
Felip, E,
Lau, YY,
Vansteenkiste, J,
Goldwasser, M,
Wolf, J,
De Pas, T,
Santoro, A,
Riely, GJ,
Camidge, DR
|
N. Engl. J. Med. |
2014 |
| 26708155 |
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Gold, KA,
Socinski, MA,
Chao, BH,
Borghaei, H,
Henschel, V,
Gandhi, L,
Ou, SI,
Shaw, AT,
Balas, B,
Puig, O,
Chiappori, A,
Zeaiter, A,
Gadgeel, S,
Bordogna, W,
Riely, GJ,
Mekhail, T,
Cetnar, J,
West, H,
Camidge, DR
|
Lancet Oncol. |
2016 |
| 31585938 |
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
Friboulet, L,
Solary, E,
Deas, O,
Thiery, JP,
Bahleda, R,
Naltet, C,
Tesson, P,
Samofalova, D,
Richon, C,
Braye, F,
Facchinetti, F,
Galissant, J,
Mahjoubi, L,
Gazzah, A,
Angevin, E,
Nicotra, C,
Scoazec, JY,
Hollebecque, A,
Olaussen, KA,
Lavaud, P,
Soria, JC,
Planchard, D,
Bigot, L,
Andre, F,
Tselikas, L,
Frias, RL,
Recondo, G,
Eggermont, AM,
Sourisseau, T,
Ngo-Camus, M,
Besse, B,
Michiels, S,
Howarth, K,
Abou Lovergne, A,
Massard, C,
De Baere, T,
Vassal, G,
Lacroix, L,
Rizvi, AZ,
Mezquita, L,
Auger, N
|
Clin. Cancer Res. |
2020 |
| 22162641 |
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
Ou, SH
|
Drug Des Devel Ther |
2011 |
